Whats included
The STEP 4 trial, which specifically examined semaglutide withdrawal, showed that participants who stopped the medication regained 6.9% of body weight over 48 weeks, while those who continued treatment lost an additional 7.9%
A groundbreaking study presented at the 2024 American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting offers a clear answer and it could reshape the conversation around medical versus surgical weight loss
Automated insulin delivery is the new standard for type 1 diabetes
The Fund is an actively managed exchange-traded fund (ETF) that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss (GLP-1 & Weight Loss Drugs)
doi: 10.7326/ACPJ202011170-052 [DOI] [PubMed] [Google Scholar] 100.Simms-Williams N, Treves N, Yin H, et al
